ESR2 and breast cancer: Another similar result was also observed in breast cancer cells by Chen et al. (2013), showing that formononetin (≥50 μM) decreased expression of miR-375 but was followed by enhanced estrogen receptor beta (ERβ) expression level, which has been associated to anti-proliferative effect, especially ERβ1 (Akiyama et al., 1992; Dey et al., 2012).